Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$30.8 million.

  • Editas Medicine's Cash from Operations rose 4134.97% to -$30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$179.6 million, marking a year-over-year increase of 118.07%. This contributed to the annual value of -$210.3 million for FY2024, which is 5909.15% down from last year.
  • Editas Medicine's Cash from Operations amounted to -$30.8 million in Q3 2025, which was up 4134.97% from -$50.2 million recorded in Q2 2025.
  • Editas Medicine's Cash from Operations' 5-year high stood at -$22.2 million during Q4 2023, with a 5-year trough of -$57.1 million in Q2 2024.
  • For the 5-year period, Editas Medicine's Cash from Operations averaged around -$42.8 million, with its median value being -$42.3 million (2022).
  • In the last 5 years, Editas Medicine's Cash from Operations skyrocketed by 4738.96% in 2023 and then tumbled by 12824.64% in 2024.
  • Quarter analysis of 5 years shows Editas Medicine's Cash from Operations stood at -$34.6 million in 2021, then dropped by 22.24% to -$42.3 million in 2022, then surged by 47.39% to -$22.2 million in 2023, then crashed by 128.25% to -$50.8 million in 2024, then soared by 39.24% to -$30.8 million in 2025.
  • Its Cash from Operations was -$30.8 million in Q3 2025, compared to -$50.2 million in Q2 2025 and -$47.8 million in Q1 2025.